These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23793108)

  • 1. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
    Gelber AC; Manno RL; Shah AA; Woods A; Le EN; Boin F; Hummers LK; Wigley FM
    Medicine (Baltimore); 2013 Jul; 92(4):191-205. PubMed ID: 23793108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non-African Americans.
    Moore DF; Kramer E; Eltaraboulsi R; Steen VD
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1154-1163. PubMed ID: 30821906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
    Greidinger EL; Flaherty KT; White B; Rosen A; Wigley FM; Wise RA
    Chest; 1998 Sep; 114(3):801-7. PubMed ID: 9743170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.
    Morgan ND; Shah AA; Mayes MD; Domsic RT; Medsger TA; Steen VD; Varga J; Carns M; Ramos PS; Silver RM; Schiopu E; Khanna D; Hsu V; Gordon JK; Gladue H; Saketkoo LA; Criswell LA; Derk CT; Trojanowski MA; Shanmugam VK; Chung L; Valenzuela A; Jan R; Goldberg A; Remmers EF; Kastner DL; Wigley FM; Gourh P; Boin F
    Medicine (Baltimore); 2017 Dec; 96(51):e8980. PubMed ID: 29390428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
    Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
    Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial differences in scleroderma among women in Michigan.
    Laing TJ; Gillespie BW; Toth MB; Mayes MD; Gallavan RH; Burns CJ; Johanns JR; Cooper BC; Keroack BJ; Wasko MC; Lacey JV; Schottenfeld D
    Arthritis Rheum; 1997 Apr; 40(4):734-42. PubMed ID: 9125258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. African American race associated with body image dissatisfaction among patients with systemic sclerosis.
    Nusbaum JS; Gordon JK; Steen VD
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):70-73. PubMed ID: 27192123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
    Igusa T; Hummers LK; Visvanathan K; Richardson C; Wigley FM; Casciola-Rosen L; Rosen A; Shah AA
    Ann Rheum Dis; 2018 Aug; 77(8):1179-1186. PubMed ID: 29678941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-U3 RNP autoantibodies in systemic sclerosis.
    Aggarwal R; Lucas M; Fertig N; Oddis CV; Medsger TA
    Arthritis Rheum; 2009 Apr; 60(4):1112-8. PubMed ID: 19333934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.
    Steen V; Domsic RT; Lucas M; Fertig N; Medsger TA
    Arthritis Rheum; 2012 Sep; 64(9):2986-94. PubMed ID: 22576620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.
    Mendes C; Viana VST; Pasoto SG; Leon EP; Bonfa E; Sampaio-Barros PD
    Clin Rheumatol; 2020 Jan; 39(1):9-17. PubMed ID: 31065858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Observational Study of Disease Severity and Mortality in Hispanic American Patients With Systemic Sclerosis.
    Jandali B; Lyons M; Charles J; Zhang M; Theodore S; Pedroza C; Mayes MD; Assassi S
    Arthritis Care Res (Hoboken); 2024 Jun; 76(6):768-776. PubMed ID: 38221717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
    Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
    Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.
    McNearney TA; Reveille JD; Fischbach M; Friedman AW; Lisse JR; Goel N; Tan FK; Zhou X; Ahn C; Feghali-Bostwick CA; Fritzler M; Arnett FC; Mayes MD
    Arthritis Rheum; 2007 Mar; 57(2):318-26. PubMed ID: 17330281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.
    Jewett LR; Kwakkenbos L; Carrier ME; Malcarne VL; Bartlett SJ; Furst DE; Gottesman K; Mayes MD; Assassi S; Harcourt D; Williamson H; Johnson SR; Körner A; Steen V; Fox RS; Gholizadeh S; Mills SD; Molnar JC; Rice DB; Thombs BD;
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):92-99. PubMed ID: 27494308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and insurance status as risk factors for trauma mortality.
    Haider AH; Chang DC; Efron DT; Haut ER; Crandall M; Cornwell EE
    Arch Surg; 2008 Oct; 143(10):945-9. PubMed ID: 18936372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
    Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
    Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.
    Mayes MD; Lacey JV; Beebe-Dimmer J; Gillespie BW; Cooper B; Laing TJ; Schottenfeld D
    Arthritis Rheum; 2003 Aug; 48(8):2246-55. PubMed ID: 12905479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.
    Pokeerbux MR; Giovannelli J; Dauchet L; Mouthon L; Agard C; Lega JC; Allanore Y; Jego P; Bienvenu B; Berthier S; Mekinian A; Hachulla E; Launay D
    Arthritis Res Ther; 2019 Apr; 21(1):86. PubMed ID: 30944015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Scleroderma Autoantibody Profiles Stratify Patients for Cancer Risk at Scleroderma Onset and During the Disease Course.
    Kim JS; Woods A; Gutierrez-Alamillo L; Laffoon M; Wigley FM; Hummers LK; Rosen A; Zeger S; Domsic RT; Casciola-Rosen L; Shah AA
    Arthritis Rheumatol; 2024 Jan; 76(1):68-77. PubMed ID: 37488962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.